Navigation Links
RELAX-AHF: Poor diuretic response associated with worse clinical outcomes
Date:5/17/2014

Athens, 17 May 2014: Poor diuretic response is associated with worse in-hospital and post-discharge clinical outcomes, results of the RELAX-AHF trial reveal. The study also found that serelaxin has a neutral effect on diuretic response.

These novel data from the RELAX-AHF trial were presented by lead author Professor Adriaan A. Voors at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.

RELAX-AHF was a double blind, placebo-controlled trial of 1161 patients admitted to hospital with acute heart failure. Patients were randomised to receive 48-hour infusions of placebo or serelaxin (30g/kg per day) within 16 hours from presentation. Primary analysis of the study showed that serelaxin reduced dyspnoea and decreased 180 day mortality.1

The current substudy, presented for the first time today, had two aims. The first was to confirm preliminary findings of the PROTECT trial, which found that poor diuretic response is a serious clinical problem.2 The second was to investigate whether the beneficial effects of serelaxin discovered in the primary analysis were related to improvement of the diuretic response.

Diuretic response was defined as kilograms of weight loss per 40mg of the loop diuretic furosemide. Professor Voors said: "Congestion is the main problem in patients with acute decompensated heart failure and we give them loop diuretics to get rid of the excess fluid. Patients who respond to the loop diuretic have diuresis and lose weight. But a substantial proportion do not respond to the diuretic, do not diurese and do not lose weight."

He added: "Diuretic response could be measured by urinary output but when patients no longer need a catheter it is difficult to capture how much fluid they have lost. We therefore used weight loss as a more objective and reliable measurement of diuretic response. The more weight patients lost per mg of furosemide given, the better their diuretic response."

The study found that diuretic response was an important clinical problem, confirming preliminary results from the PROTECT trial. Patients with a poor diuretic response had less dyspnoea relief (p=0.0001) and a higher risk of cardiovascular death or rehospitalisation for heart failure or renal failure through day 60 (p<0.004). Poor diuretic response was not associated with increased 180-day cardiovascular mortality (p=0.546).

Professor Voors said: "The most important message from this substudy is that if patients are hospitalised for acute heart failure and do not respond well to their diuretic then they are in trouble. Their recovery in hospital is likely to be worse and when they are sent home there is a good chance that they will be rehospitalised again or even die."

The next question was whether serelaxin influenced patients' response to diuretics. The researchers found that serelaxin had no effect on diuretic response. Patients in the serelaxin group improved clinically and were given fewer diuretics but they lost less weight than the placebo group.

Professor Voors said: "Patients felt better with serelaxin and so physicians gave them less diuretics. But these patients did not diurese more, so the overall effect of serelaxin on diuretic response was neutral."

He added: "We will continue to look for the mechanisms by which serelaxin exerts its positive effects. The current study shows that the beneficial effects of serelaxin are not through improvement of diuretic response. We have already shown that serelaxin prevents the organ damage that occurs during an episode of acute heart failure3 and we will continue to investigate other modes of action."

Professor Voors concluded: "The major finding from this substudy of the RELAX-AHF trial is that diuretic resistance is a clinical problem that leads to worse in-hospital and early post-discharge clinical outcomes in patients with acute heart failure. More insights are needed into the problem of poor diuretic response so that better therapies can be found to improve the diuretic response and improve clinical outcomes."


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-622-834-576
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Black patients with hypertension not prescribed diuretics enough
2. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
3. Response to First Treatment May Predict Epilepsys Course
4. Genetic predictor of breast cancer response to chemotherapy
5. Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels
6. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
7. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
8. Babies susceptibility to colds linked to immune response at birth
9. Biomarker predicts response to cancer treatment
10. Baseline characteristics of children with mild persistent asthma predict response to ICS
11. Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 23, 2017 , ... "The Better Care Reconciliation Act (BCRA) ... to people with all chronic conditions, including mental illnesses, while increasing the cost ... Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... practicing in Newburgh, New York, has recently begun offering three new minimally invasive ... the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to bring ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... and two new videos highlight the importance of correctly using a meat thermometer. ... who has done extensive research on consumer food safety habits. Dr. Bruhn explains ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update of flood ... States. In 2012, the Biggert-Waters Act was enacted to reflect the actual risk ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that ... eastern Texas, is announcing the launch of a new charity drive to benefit women ... the United States reveal that an estimated 252, 710 new cases of invasive or ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... it will be presenting at the 7th annual LD Micro Invitational ... Raphael , CEO, of DarioHealth will be giving the presentation and ... June 6th & 7th, 2017 at the Luxe Sunset Bel Air ... space. About LD Micro LD ...
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
Breaking Medicine Technology: